Publications in OpenAlex of which a co-author is affiliated to this organization
All publications | By field | By subfield
All publications [Next]
| Title | DOI |
|---|---|
| https://doi.org/10.1177/0962280207081864 | Individual- and trial-level surrogacy in colorectal cancer |
| https://doi.org/10.1046/j.1468-2982.2000.00069.x | Comparison of Rizatriptan 10 Mg vs. Zolmitriptan 2.5 Mg in the Acute Treatment of Migraine |
| https://doi.org/10.1017/s0266462314000300 | VALIDATION OF SURROGATE ENDPOINTS IN ADVANCED SOLID TUMORS: SYSTEMATIC REVIEW OF STATISTICAL METHODS, RESULTS, AND IMPLICATIONS FOR POLICY MAKERS |
| https://doi.org/10.1093/annonc/mdp011 | Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial) |
| https://doi.org/10.1182/blood-2011-02-337725 | Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia |
| https://doi.org/10.1093/annonc/mdv562 | Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agents |
| https://doi.org/10.1200/jco.2007.12.1368 | End Points in Advanced Colon Cancer Clinical Trials: A Review and Proposal |
| https://doi.org/10.1158/1078-0432.ccr-14-2993 | PTEN Loss Is Associated with Worse Outcome in HER2 -Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance |
| https://doi.org/10.1093/jnci/djx179 | Understanding and Communicating Measures of Treatment Effect on Survival: Can We Do Better? |
| https://doi.org/10.1007/s00280-013-2262-2 | Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2-positive breast cancer: an NSABP Foundation Research Program phase I study |
| https://doi.org/10.3816/cbc.2010.n.011 | A Phase II Neoadjuvant Trial of Sequential Nanoparticle Albumin-Bound Paclitaxel Followed by 5-Fluorouracil/Epirubicin/Cyclophosphamide in Locally Advanced Breast Cancer |
| https://doi.org/10.1200/jco.2011.38.6359 | Overall Survival: Patient Outcome, Therapeutic Objective, Clinical Trial End Point, or Public Health Measure? |
| https://doi.org/10.3132/dvdr.2007.064 | The European Perspective on Diabetes Prevention: development and Implementation of A European Guideline and training standards for diabetes prevention (IMAGE) |
| https://doi.org/10.1093/annonc/mdw098 | Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial |
| https://doi.org/10.1186/bcr3179 | Prognostic and predictive value of TP53mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial |
| https://doi.org/10.1016/j.breast.2014.02.009 | The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: First-year results from the Compliance of ARomatase Inhibitors AssessmenT In Daily practice through Educational approach (CARIATIDE) study |
| https://doi.org/10.1200/jco.19.03114 | Event-Free Survival, a Prostate-Specific Antigen–Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation |
| https://doi.org/10.1191/0962280204sm362ra | A perspective on surrogate endpoints in controlled clinical trials |
| https://doi.org/10.1177/1740774506070807 | Impact of on-site initiation visits on patient recruitment and data quality in a randomized trial of adjuvant chemotherapy for breast cancer |
| https://doi.org/10.1136/bmjopen-2017-017075 | Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types |
| https://doi.org/10.1016/j.ophtha.2014.07.043 | Stereotactic Radiotherapy for Neovascular Age-Related Macular Degeneration |
| https://doi.org/10.1186/s13058-019-1196-y | NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer |
| https://doi.org/10.1093/annonc/mdv259 | St Gallen International Expert Consensus on the primary therapy of early breast cancer: an invaluable tool for physicians and scientists |
| https://doi.org/10.1080/0094965031000062177 | Simplified hierarchical linear models for the evaluation of surrogate endpoints |
| https://doi.org/10.1038/bjc.2011.235 | Designing phase II trials in cancer: a systematic review and guidance |
| https://doi.org/10.1002/sim.6294 | Linear mixed‐effects models for central statistical monitoring of multicenter clinical trials |
| https://doi.org/10.1200/jco.2010.34.0380 | Progression-Free Survival Ratio As End Point for Phase II Trials in Advanced Solid Tumors |
| https://doi.org/10.3233/jad-150429 | Protein Kinase Activity Decreases with Higher Braak Stages of Alzheimer’s Disease Pathology |
| https://doi.org/10.1016/s1470-2045(21)00077-2 | The International Collaboration for Research methods Development in Oncology (CReDO) workshops: shaping the future of global oncology research |
| https://doi.org/10.3324/haematol.2010.039131 | Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission |
| https://doi.org/10.1007/s40265-017-0728-y | Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors |
| https://doi.org/10.1016/j.ejca.2015.03.018 | Final 10-year results of the Breast International Group 2–98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer |
| https://doi.org/10.1200/jco.2011.38.4206 | Survival Is Not a Good Outcome for Randomized Trials With Effective Subsequent Therapies |
| https://doi.org/10.1634/theoncologist.2011-0212 | Correlation Between Quantitative HER-2 Protein Expression and Risk for Brain Metastases in HER-2+ Advanced Breast Cancer Patients Receiving Trastuzumab-Containing Therapy |
| https://doi.org/10.1111/jch.12840 | High Blood Pressure 2016: Why Prevention and Control Are Urgent and Important. The World Hypertension League, International Society of Hypertension, World Stroke Organization, International Diabetes Foundation, International Council of Cardiovascular Prevention and Rehabilitation, International Society of Nephrology |
| https://doi.org/10.1001/jamaoncol.2018.6012 | Assessment ofERBB2/HER2Status inHER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines |
| https://doi.org/10.2217/fon-2019-0201 | Devimistat in Combination with High Dose Cytarabine and Mitoxantrone Compared with High Dose Cytarabine and Mitoxantrone in Older Patients with Relapsed/Refractory Acute Myeloid Leukemia: ARMADA 2000 Phase III Study |
| https://doi.org/10.1016/j.csda.2011.03.014 | Comparative assessment of trial-level surrogacy measures for candidate time-to-event surrogate endpoints in clinical trials |
| https://doi.org/10.1186/s13058-019-1240-y | Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer |
| https://doi.org/10.1038/s41375-020-0733-0 | ATIR101 administered after T-cell-depleted haploidentical HSCT reduces NRM and improves overall survival in acute leukemia |
| https://doi.org/10.2217/fon.14.179 | Does patient education work in breast cancer? Final results from the global CARIATIDE study |
| https://doi.org/10.1038/bjc.2015.55 | Assessing the benefit–risk of new treatments using generalised pairwise comparisons: the case of erlotinib in pancreatic cancer |
| https://doi.org/10.1016/j.cct.2020.106189 | Infectious diseases epidemiology, quantitative methodology, and clinical research in the midst of the COVID-19 pandemic: Perspective from a European country |
| https://doi.org/10.1016/j.ejca.2023.02.002 | Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial |
| https://doi.org/10.1016/j.ejca.2014.08.017 | Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity? |
| https://doi.org/10.1093/annonc/mdq406 | Neoadjuvant capecitabine and docetaxel (plus trastuzumab): an effective non-anthracycline-based chemotherapy regimen for patients with locally advanced breast cancer |
| https://doi.org/10.1186/s13058-019-1115-2 | PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial |
| https://doi.org/10.3747/co.v18is2.941 | Progression-Free Survival as a Primary Endpoint in Clinical Trials of Metastatic Colorectal Cancer |
| https://doi.org/10.1177/009286150003400207 | Randomized Designs for Early Trials of New Cancer Treatments—An Overview |
| https://doi.org/10.1182/blood-2019-123219 | A Phase 1 Study of ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma |
| https://doi.org/10.1016/j.ygyno.2019.11.034 | A randomized phase III trial in patients with recurrent platinum sensitive ovarian cancer comparing efficacy and safety of paclitaxel micellar and Cremophor EL-paclitaxel |
| https://doi.org/10.1182/blood-2020-135941 | ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma |
| https://doi.org/10.4103/2229-3485.154016 | Common pitfalls in statistical analysis: "P" values, statistical significance and confidence intervals |
| https://doi.org/10.1158/1078-0432.ccr-20-1831 | Neratinib-Plus-Cetuximab in Quadruple-WT ( KRAS, NRAS, BRAF, PIK3CA ) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study |
| https://doi.org/10.1111/biom.12483 | An Information-Theoretic Approach for the Evaluation of Surrogate Endpoints Based on Causal Inference |
| https://doi.org/10.1007/s00415-016-8051-1 | Normalisation of brain spectroscopy findings in Niemann–Pick disease type C patients treated with miglustat |
| https://doi.org/10.1016/j.jtho.2019.05.030 | Chronological Trends in Progression-Free, Overall, and Post-Progression Survival in First-Line Therapy for Advanced NSCLC |
| https://doi.org/10.1093/annonc/mdp012 | FOLFOX in patients with metastatic colorectal cancer and high alkaline phosphatase level: an exploratory cohort of the GERCOR OPTIMOX1 study |
| https://doi.org/10.1177/1740774519862564 | Detection of atypical data in multicenter clinical trials using unsupervised statistical monitoring |
| https://doi.org/10.1080/10428194.2022.2043304 | Momelotinib reduces transfusion requirements in patients with myelofibrosis |
| https://doi.org/10.1200/jco.2013.31.15_suppl.tps8121 | A phase III comparative study of nivolumab (anti-PD-1; BMS-963558; ONO-4538) versus docetaxel in patients (pts) with previously treated advanced/metastatic nonsquamous non-small-cell lung cancer (NSCLC). |
| https://doi.org/10.1177/1740774517716158 | The impact of data errors on the outcome of randomized clinical trials |
| https://doi.org/10.1200/jco.2020.38.15_suppl.3056 | A phase I study of ALX148, a CD47 blocker, in combination with standard anticancer antibodies and chemotherapy regimens in patients with advanced malignancy. |
| https://doi.org/10.1177/0962280217718582 | A Poisson approach to the validation of failure time surrogate endpoints in individual patient data meta-analyses |
| https://doi.org/10.1111/biom.12583 | Estimation of Diagnostic Accuracy of a Combination of Continuous Biomarkers Allowing for Conditional Dependence Between the Biomarkers and the Imperfect Reference-Test |
| https://doi.org/10.1158/1078-0432.ccr-21-1762 | Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer |
| https://doi.org/10.1200/jco.2022.40.16_suppl.4023 | Phase 3, multicenter, randomized study of CPI-613 with modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) as first-line therapy for patients with metastatic adenocarcinoma of the pancreas (AVENGER500). |
| https://doi.org/10.1200/jco.2012.30.15_suppl.611 | A phase I dose-escalation study evaluating weekly paclitaxel with neratinib and trastuzumab in women with metastatic HER2-positive breast cancer, NSABP FB-8. |
| https://doi.org/10.1200/jco.2017.35.15_suppl.1002 | A phase II trial of the CDK4/6 inhibitor palbociclib (P) as single agent or in combination with the same endocrine therapy (ET) received prior to disease progression, in patients (pts) with hormone receptor positive (HR+) HER2 negative (HER2−) metastatic breast cancer (mBC) (TREnd trial). |
| https://doi.org/10.1007/s43441-021-00341-5 | Detection of Fraud in a Clinical Trial Using Unsupervised Statistical Monitoring |
| https://doi.org/10.1016/j.annonc.2023.11.017 | Validation of metastasis-free survival as a surrogate endpoint for overall survival in localized prostate cancer in the era of docetaxel for castration-resistant prostate cancer |
| https://doi.org/10.1001/jamanetworkopen.2019.11750 | Evaluation of Continuous Tumor-Size–Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer |
| https://doi.org/10.1177/17407745231206465 | Design of a clinical trial using generalized pairwise comparisons to test a less intensive treatment regimen |
| https://doi.org/10.1158/1538-7445.sabcs14-s6-01 | Abstract S6-01: Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: BOLERO-1 |
| https://doi.org/10.1016/j.clbc.2016.07.008 | Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5 |
| https://doi.org/10.1080/0284186x.2020.1871067 | Rationale and design of REGINA, a phase II trial of neoadjuvant regorafenib, nivolumab, and short-course radiotherapy in stage II and III rectal cancer |
| https://doi.org/10.1007/s13300-021-01030-0 | Impact of Age on the Effectiveness and Safety of Insulin Glargine 300 U/mL: Results from the REALI European Pooled Data Analysis |
| https://doi.org/10.1016/j.radonc.2021.04.006 | Independent external validation using the EORTC HNCG-ROG 1219 DAHANCA trial data of NTCP models for acute oral mucositis |
| https://doi.org/10.1016/j.adro.2024.101674 | Benefit of Avasopasem Manganese on Severe Oral Mucositis in Head and Neck Cancer in the ROMAN Trial: Unplanned Secondary Analysis |
| https://doi.org/10.1002/pst.2156 | Operational characteristics of generalized pairwise comparisons for hierarchically ordered endpoints |
| https://doi.org/10.1136/jitc-2021-sitc2021.498 | 498 Evorpacept (ALX148), a CD47 myeloid checkpoint inhibitor, in patients with head and neck squamous cell carcinoma (HNSCC) and with gastric/gastroesophageal cancer (GC); ASPEN-01 |
| https://doi.org/10.1002/bimj.201900354 | A new measure of treatment effect in clinical trials involving competing risks based on generalized pairwise comparisons |
| https://doi.org/10.1093/jnci/djad152 | Time to deterioration of patient-reported outcomes as a surrogate of overall survival: a meta-analysis |
| https://doi.org/10.1002/sim.8788 | Net benefit in the presence of correlated prioritized outcomes using generalized pairwise comparisons: A simulation study |
| https://doi.org/10.1002/pst.2165 | Using an interim analysis based exclusively on an early outcome in a randomized clinical trial with a long‐term clinical endpoint |
| https://doi.org/10.1093/jnci/djab218 | Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology |
| https://doi.org/10.1200/jco.23.01196 | Early Efficacy End Points in Neoadjuvant Rectal Cancer Trials: Surrogacy Revisited |
| https://doi.org/10.1007/s43441-024-00613-w | Does Central Statistical Monitoring Improve Data Quality? An Analysis of 1,111 Sites in 159 Clinical Trials |
| https://doi.org/10.1186/s13058-024-01823-8 | NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer |
| https://doi.org/10.1200/jco.24.00539 | Clinical Study Report and Individual Participant Data Transparency for US Food and Drug Administration–Approved Anticancer Drugs: A Call for Systematic Data Availability |
| https://doi.org/10.1007/s43441-022-00470-5 | Does Central Monitoring Lead to Higher Quality? An Analysis of Key Risk Indicator Outcomes |
| https://doi.org/10.1111/epi.13410 | Disruption, but not overexpression of urate oxidase alters susceptibility to pentylenetetrazole‐ and pilocarpine‐induced seizures in mice |
| https://doi.org/10.1080/00015458.2018.1470276 | Impact of a prehospital discrimination between trauma patients with or without early acute coagulopathy of trauma and the need for damage control resuscitation: rationale and design of a multicenter randomized phase II trial |
| https://doi.org/10.1053/j.sodo.2025.06.002 | Comparing prescribed and achieved treatment outcomes in digitally planned orthodontic treatment: statistical approaches |
| https://doi.org/10.1002/pst.2271 | On the use of extreme value tail modeling for generalized pairwise comparisons with censored outcomes |
| https://doi.org/10.1186/s13023-023-02943-8 | Generalized pairwise comparisons of prioritized outcomes are a powerful and patient-centric analysis of multi-domain scores |
| https://doi.org/10.1016/j.esmogo.2024.100067 | Efficacy and safety of short-course radiotherapy versus total neoadjuvant therapy in older rectal cancer patients: a randomised pragmatic trial (SHAPERS) |
| https://doi.org/10.1016/j.eclinm.2025.103465 | Use of surrogate endpoints in health technology assessment and reimbursement of treatments for the management of chronic kidney disease |
| https://doi.org/10.1200/jco.2023.41.16_suppl.5073 | The relationship between a priori defined prognostic risk groups and and overall survival (OS) in men with metastatic hormone sensitive prostate cancer (mHSPC). |
| https://doi.org/10.1016/j.jclinepi.2024.111340 | Restricted Net Treatment Benefit in oncology |